The effects of an alpha-2-adrenoceptor agonist, antagonist, and their combination on the blood insulin, glucose, and glucagon concentrations in insulin sensitive and dysregulated horses.
Authors: Box J R, Karikoski N P, Tanskanen H E, Raekallio M R
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary Alpha-2-adrenoceptor agonists like detomidine are commonly used sedatives in equine practice, yet their effects on glucose metabolism remain problematic—particularly in horses with insulin dysregulation, where metabolic stability is already compromised. Box and colleagues investigated whether vatinoxan, an alpha-2-adrenoceptor antagonist, could mitigate detomidine's metabolic side effects by administering detomidine alone, vatinoxan alone, both drugs together, or saline to eight insulin-dysregulated and eight metabolically normal horses in a blinded cross-over trial, with blood samples collected at hourly intervals for eight hours. Detomidine alone induced significant hyperglycaemia and hyperinsulinaemia at 1–4 hours post-administration in both groups, whilst the combination of detomidine and vatinoxan substantially blunted these responses, particularly in dysregulated horses where insulin concentrations remained comparable to saline controls. The practical implication is substantial: when sedating insulin-dysregulated horses—a population at elevated risk of laminitis—concurrent vatinoxan administration may preserve glucose homeostasis and reduce iatrogenic metabolic stress, potentially making detomidine a safer choice for these metabolically vulnerable animals where sedation is clinically necessary.
Read the full abstract on PubMed
Practical Takeaways
- •Vatinoxan co-administration should be considered when using detomidine for sedation in horses with insulin dysregulation to prevent adverse glucose and insulin fluctuations
- •Clinicians using detomidine in horses with suspected or confirmed insulin dysregulation should monitor blood glucose and insulin concentrations, as hyperglycaemia and hyperinsulinaemia can occur within 2-4 hours
- •Detomidine monotherapy causes significant metabolic derangements in insulin-dysregulated horses; combination therapy or alternative sedatives may be safer choices for this population
Key Findings
- •Detomidine caused hyperglycaemia at 1-2 hours and hyperinsulinaemia at 2-4 hours in both insulin dysregulated and non-dysregulated horses
- •Vatinoxan (alpha-2 antagonist) effectively prevented detomidine-induced hyperglycaemia and subsequent insulin elevation in horses with insulin dysregulation
- •Combined detomidine + vatinoxan treatment produced blood glucose levels intermediate between detomidine alone and saline control at 1 hour
- •Detomidine reduced glucagon levels at 1-2 hours in both groups compared to saline control